EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes

Tobias Ruck, Niklas Huntemann, Menekse Öztürk, Stefanie Schreiber, Stefanie Lichtenberg, Lars Masanneck, Christopher Nelke, Hend Ben Moussa, Thomas Ulrych, Marc Seifert, Dimitrios Mougiakakos, Sascha Dietrich und 1 weitere

Molecular Therapy · 2025-09 · 33 (9) · 4135-4142

DOI: 10.1016/j.ymthe.2025.06.042 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Therapy, 2025-09. Verfasst von Tobias Ruck und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ruhr University Bochum, BG University Hospital Bergmannsheil, Department of Neurology, 44789 Bochum, Germany; BG University Hospital Bergmannsheil, H…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antigens, CD19, Myasthenia Gravis, T-Lymphocytes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this case series, we report the first off-label use of the CD19xCD3 T cell engager blinatumomab in two patients with generalized myasthenia gravis (MG). Refractory MG remains a major therapeutic challenge, with patients experiencing severe disability and potentially life-threatening crises despite intensive immunotherapy. This study evaluates the clinical efficacy and safety of short-term blinatumomab treatment in two patients with severe, refractory generalized MG. Both individuals had been experiencing persistent disease burden with myasthenic crises leading to severe disability, despite multimodal immunotherapy. Following treatment with blinatumomab, both patients showed rapid and sustained clinical improvements, reflected in significant reductions in MG-specific scores (MG Activities of Daily Living scale, Quantitative MG score, and revised MG Quality of Life-15), further patient-reported outcomes, digital activity markers, and gait analyses. Laboratory findings revealed persistent B cell depletion in patient 1, whereas patient 2 demonstrated clinical improvement and autoantibody reduction despite B cell repopulation by day 106. Both patients experienced grade 1 cytokine release syndrome during initial treatment phases, but no neurotoxicity or severe adverse events were observed. This report underscores the potential of CD19xCD3 T cell engagers as a promising therapeutic approach in severe autoimmune neuroimmunological disorders, warranting further investigation in clinical trials and mechanistic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntigens, CD19Myasthenia GravisT-LymphocytesAdultFemaleHumansMiddle AgedCD3 ComplexImmunotherapyQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

BiTELEMSLambert-Eaton myasthenic syndromeMGT cell engagerblinatumomabmyasthenia gravisneuroimmunologyneuromuscular diseaserefractory MG

Substanzen

Antibodies, BispecificAntigens, CD19blinatumomabCD3 Complex

Autor:innen und Institutionen

  • Ruhr University Bochum, BG University Hospital Bergmannsheil, Department of Neurology, 44789 Bochum, Germany; BG University Hospital Bergmannsheil, Heimer Institute for Muscle Research, 44789 Bochum, Germany; Department…
  • Department of Neurology, University Hospital and Medical Faculty Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
  • Department of Neurology, University Hospital and Medical Faculty Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; Department of Neurology, Otto von Guericke University Magdeburg, 39120 Magdeb…
  • Department of Haematology and Oncology, University Hospital Düsseldorf, and Center for Integrated Oncology Aachen Bonn Cologne, 40225 Düsseldorf, Germany.
  • Department of Haematology, Oncology, and Cell Therapy, Otto von Guericke University Magdeburg, 39120 Magdeburg, Germany.

Förderung

  • German Research Foundation
  • European Regional Development Fund

Zitieren

APA

Ruck, T., Huntemann, N., Öztürk, M., Schreiber, S., Lichtenberg, S., Masanneck, L., Nelke, C., Ben Moussa, H., Ulrych, T., Seifert, M., Mougiakakos, D., Dietrich, S., & Meuth, S. G. (2025). CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes. Molecular Therapy, 33(9), 4135-4142. https://doi.org/10.1016/j.ymthe.2025.06.042

Vancouver

Ruck T, Huntemann N, Öztürk M, Schreiber S, Lichtenberg S, Masanneck L, et al. CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes. Molecular Therapy. 2025;33(9):4135-4142. doi:10.1016/j.ymthe.2025.06.042

BibTeX
@article{Ruck2025,
  author = {Ruck, Tobias and Huntemann, Niklas and Öztürk, Menekse and Schreiber, Stefanie and Lichtenberg, Stefanie and Masanneck, Lars and Nelke, Christopher and Ben Moussa, Hend and Ulrych, Thomas and Seifert, Marc and Mougiakakos, Dimitrios and Dietrich, Sascha and Meuth, Sven G},
  title = {CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {9},
  pages = {4135--4142},
  doi = {10.1016/j.ymthe.2025.06.042}
}
Kostenlos starten →